Kir3.1抑制剂(potassium inwardly rectifying channel subfamily J member 3 inhibitors)、Kir3.4抑制剂(potassium inwardly rectifying channel subfamily J member 5 inhibitors)

治疗领域

心血管疾病

在研适应症-

非在研适应症

心律失常

原研机构

阿斯利康制药有限公司

在研机构-

非在研机构

AstraZeneca PLC

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H25FN2O2

InChIKeyGAHPWXLXWUVMIV-MRXNPFEDSA-N

CAS号1380100-86-6

关联

项与 AZD-2927 相关的临床试验

NCT01396226

/ Completed临床2期

A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure

Medical Products Agency

开始日期2011-09-01

申办/合作机构

AstraZeneca PLC

NCT01264250

/ Completed临床1期

A Phase I, Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Subjects

In this early phase study, healthy male volunteers will be randomly assigned to one dose of either AZD2927 or placebo. The objective will be to assess the Safety,Tolerability and Pharmacokinetics of AZD2927.

开始日期2011-01-01

申办/合作机构

AstraZeneca PLC

100 项与 AZD-2927 相关的临床结果

登录后查看更多信息

100 项与 AZD-2927 相关的转化医学

登录后查看更多信息

100 项与 AZD-2927 相关的专利（医药）

登录后查看更多信息

项与 AZD-2927 相关的文献（医药）

2015-03-01·EP Europace2区 · 医学

Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans

2区 · 医学

Article

作者: Jensen, Steen ; Berggren, Anders ; Walfridsson, Håkan ; Anfinsen, Ole-Gunnar ; Nordkam, Ann-Christin ; Sundqvist, Monika ; Linhardt, Gunilla ; Frison, Lars ; Carlsson, Leif

AIMSWe aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target for the management of atrial fibrillation (AF).METHODS AND RESULTSThe investigative agents AZD2927 and A7071 concentration-dependently blocked IKACh in vitro with minimal off-target activity. In anaesthetized dogs (n = 17) subjected to 8 weeks of rapid atrial pacing (RAP), the left atrial effective refractory period (LAERP) was maximally increased by 50 ± 7.4 and 50 ± 4.8 ms following infusion of AZD2927 and A7071. Ventricular refractoriness and the QT interval were unaltered. During sustained AF, both drugs significantly reduced AF frequency and effectively restored sinus rhythm. AZD2927 successfully restored sinus rhythm at 10/10 conversion attempts and A7071 at 14/14 attempts, whereas saline converted 4/17 episodes only (P<0.001 vs. AZD2927 and A7071). In atrial flutter patients (n = 18) undergoing an invasive investigation, AZD2927 did not change LAERP, the paced QT interval, or ventricular refractoriness when compared with placebo. To address the discrepancy on LAERP by IKACh blockade in man and dog and the hypothesis that atrial electrical remodelling is a prerequisite for IKACh blockade being efficient, six dogs were studied after 8 weeks of RAP followed by sinus rhythm for 4 weeks to reverse electrical remodelling. In these dogs, both AZD2927 and A7071 were as effective in increasing LAERP as in the dogs studied immediately after the 8-week RAP period.CONCLUSIONBased on the present series of experiments, an important role of IKACh in human atrial electrophysiology, as well as its potential as a viable target for effective management of AF, may be questioned.

100 项与 AZD-2927 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心律失常	临床2期	挪威	AstraZeneca PLC	2011-09-01
心律失常	临床2期	瑞典	AstraZeneca PLC	2011-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01396226 (CTgov)	临床2期	心律失常	20	AZD2927 (Arm 1 - AZD2927)	繭憲夢鹹鏇製鹽選壓糧(餘膚構觸夢襯遞遞繭憲) = 範網膚夢選壓夢鬱鏇醖築遞衊憲選淵鹽餘製鹹 (糧遞蓋繭鹹壓餘廠鹹餘, 積淵遞範鹹顧壓襯淵遞 ~ 衊餘醖網蓋鹽鹽獵壓鏇) 更多	-	2012-10-23
				Placebo (Arm 2 - PLACEBO)	繭憲夢鹹鏇製鹽選壓糧(餘膚構觸夢襯遞遞繭憲) = 選鹹鹽膚醖鏇繭淵膚衊築遞衊憲選淵鹽餘製鹹 (糧遞蓋繭鹹壓餘廠鹹餘, 鹽獵蓋鹹廠夢夢鏇獵選 ~ 糧襯糧艱醖蓋糧範鬱獵) 更多